XML 59 R65.htm IDEA: XBRL DOCUMENT
v2.4.0.6

Arrangements with Symphony Icon, Inc. (Details) (USD $) | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | ---
Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Jul. 30, 2012 | Jul. 30, 2010 | Dec. 31, 2009 | Jun. 15, 2007
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Holdings Contribution To Icon |  |  |  |  |  |  | $ 45,000,000
Lexicon Sold Shares To Holdings |  |  |  |  |  |  | 7,650,622
Lexicon Received Cash From Holdings |  |  |  |  |  |  | 15,000,000
Structuring and Legal Fees Originally Allocated to Noncontrolling Interest |  |  | 2,300,000 |  |  |  |
Cumulative Effect on Retained Earnings, before Tax |  |  | 1,500,000 |  |  |  |
Unamortized Balance of Purchase Option |  |  |  |  |  | 3,100,000 |
Amortization Expense for Purchase Option |  |  | 4,000,000 |  |  |  |
Lexicon Paid Holdings Cash |  |  |  |  | 10,000,000 |  |
Symphon Fair Value Of Base And Contingent Payments |  |  |  |  | 45,600,000 |  |
Symphony Base Payment Discount Rate |  |  |  |  | 14.00% |  |
Symphony Contingent Payment Discount Rate |  |  |  |  | 18.00% |  |
Symphony Base Payment In Shares |  |  |  | 13,237,519 |  |  |
Symphony Base Payment Obligation |  |  |  | 35,000,000 |  |  |
Symphony Contingent Payment Maximum |  |  |  |  | 45,000,000 |  |
Symphony Contingent Payment Percentage |  |  |  |  | 50.00% |  |
Symphony Regulatory Approval Payment |  |  |  |  | 15,000,000 |  |
Symphony Regulatory Approval Reduction Percentage |  |  |  |  | 50.00% |  |
Symphony Regulatory Approval Percentage Limit |  |  |  |  | 50.00% |  |
Symphony Payment In Stock Limitation |  |  |  |  | 50.00% |  |
Fair Value of Stock Issued to Holdings |  |  |  |  |  |  | 23,600,000
Increase in fair value of Symphony Icon, Inc. purchase liability | $ 9,887,000 | $ 6,766,000 | $ 2,710,000 |  |  |  |

X
- Definition Upon the exercise of the Purchase Option on July 30, 2010, the remaining balance was amortized immediately. The amortization expense of $4.0 million is recorded in other expense, net for the year ended December 31, 2010. + References No definition available. + Details
Name: | lxrx_AmortizationExpenseForPurchaseOption
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations. + References No definition available. + Details
Name: | lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Lexicon originally calculated the value of the Purchase Option as the difference between the fair value of the common stock issued to Holdings and the cash received from Holdings for the issuance of the common stock. This represents the fair value of the common stock issued to Holdings. + References No definition available. + Details
Name: | lxrx_FairValueOfStockIssuedToHoldings
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition On June 15, 2007, Symphony Icon Holdings LLC contributed $45 million to Symphony Icon in order to fund the clinical development of the Programs. + References No definition available. + Details
Name: | lxrx_HoldingsContributionToIcon
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the cash paid to Holdings. + References No definition available. + Details
Name: | lxrx_LexiconPaidHoldingsCash
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition On June 15, 2007, Lexicon issued and sold to Symphony Icon Holdings LLC 7,650,622 shares of its common stock in exchange for $15 million and an exclusive purchase option that gave Lexicon the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs. + References No definition available. + Details
Name: | lxrx_LexiconReceivedCashFromHoldings
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition On June 15, 2007, Lexicon issued and sold to Symphony Icon Holdings LLC 7,650,622 shares of its common stock in exchange for $15 million and an exclusive purchase option that gave Lexicon the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs. + References No definition available. + Details
Name: | lxrx_LexiconSoldSharesToHoldings
Namespace Prefix: | lxrx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Upon the adoption of a new accounting pronouncement regarding variable interest entities (formerly SFAS No. 167) on January 1, 2010, $2.3 million of structuring and legal fees originally allocated to noncontrolling interest was allocated to the value of the Purchase Option. + References No definition available. + Details
Name: | lxrx_StructuringAndLegalFeesOriginallyAllocatedToNoncontrollingInterest
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments. The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This represents the acquisition date fair value. + References No definition available. + Details
Name: | lxrx_SymphonFairValueOfBaseAndContingentPayments
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments. The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This represents the acquisition date discount rate for the base payment. + References No definition available. + Details
Name: | lxrx_SymphonyBasePaymentDiscountRate
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the 13,237,519 shares of common stock issued to designees of Holdings on July 30, 2012 in satisfaction of the base payment obligation. + References No definition available. + Details
Name: | lxrx_SymphonyBasePaymentInShares
Namespace Prefix: | lxrx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the $35 million base payment obligation that was paid in common stock. + References No definition available. + Details
Name: | lxrx_SymphonyBasePaymentObligation
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments. The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This represents the acquisition date discount rate for the contingent payments. + References No definition available. + Details
Name: | lxrx_SymphonyContingentPaymentDiscountRate
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the maximum amount for any contingent payment. + References No definition available. + Details
Name: | lxrx_SymphonyContingentPaymentMaximum
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the percentage of consideration received that will be paid to Holdings. + References No definition available. + Details
Name: | lxrx_SymphonyContingentPaymentPercentage
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The contingent payments to Holdings may be paid in cash or a combination of cash and common stock, in Lexicon's discretion, provided that no more than 50% of any payment will be paid in common stock. + References No definition available. + Details
Name: | lxrx_SymphonyPaymentInStockLimitation
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and any Recapture Eligible Amount attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. This represents the payment that will be made upon regulatory approval. + References No definition available. + Details
Name: | lxrx_SymphonyRegulatoryApprovalPayment
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. In the event Lexicon makes any such payment upon United States regulatory approval, Lexicon will have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed 50% of the payment made as a result of such United States regulatory approval. This represents the percentage by which proceeds of Licensing Transactions must exceed regulatory approval payments in order for Lexicon to have an obligation to make subsequent contingent payments. + References No definition available. + Details
Name: | lxrx_SymphonyRegulatoryApprovalPercentageLimit
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. This represents the percentage reduction of the regulatory approval payment by previous contingent payments. + References No definition available. + Details
Name: | lxrx_SymphonyRegulatoryApprovalReductionPercentage
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Upon the adoption of a new accounting pronouncement regarding variable interest entities (formerly SFAS No. 167) on January 1, 2010, $2.3 million of structuring and legal fees originally allocated to noncontrolling interest was allocated to the value of the Purchase Option. This resulted in a cumulative-effect adjustment to retained earnings of $1.5 million, representing the additional amortization expense that would have been recorded through December 31, 2009. The unamortized balance of $3.1 million was recorded in prepaid expenses and other current assets as of December 31, 2009. This represents the $3.1 million unamortized balance. + References No definition available. + Details
Name: | lxrx_UnamortizedBalanceOfPurchaseOption
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of the cumulative effect on retained earnings before related income tax effect. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22663-107794 + Details
Name: | us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration